Aim To characterize the usage profile and the factors associated with the prolonged use of proton pump inhibitor drugs in a community pharmacy. Methodology This is a cross-sectional, prospective and observational study involving interviews with 410 patients who acquired PPI for their own use from community pharmacies. To characterize the factors associated with the prolonged use of PPI, a multivariate logistic regression model was used. Results Pantoprazole (42.7%) and omeprazole (31%) were the most acquired PPIs, prescribed mainly by gastroenterologists (49.5%). They are used in the morning, especially for gastrointestinal symptoms, however, they had been consumed for more than 5 years in 30% of cases. The factors associated with prolonged use are old age (OR 1.03 CI95% 1.01–1.05), body mass index (OR 1.07 CI95% 1.01–1.12), use of non-steroidal anti-inflammatories (OR 3.18 CI95% 1.20–8.43) and selective serotonin reuptake inhibitors (OR 3.5 95% CI 1.39–8.88). Conclusion PPIs are adequate in terms of indication and form of use, however, prolonged use associated with old age, being overweight and use of anti-inflammatories and antidepressants is frequent.

Objective: The aim of this study is to identify the prevalence of drug interaction associated with proton pump inhibitors, associated factors and drugs involved. Methods: Cross-sectional study in 194 customers (> 18 years) of community pharmacies shortly after proton pump inhibitors acquisition (March 2019 to March 2020). Risk factors for drug interaction were assessed via multivariate logistic regression and relevance by network analysis. Results: The prevalence of drug interaction was 16.4% and was related to older age (OR=1.05; 95%CI 1.03 - 1.07) and female sex (OR=2.27; 95%CI 1, 15 - 4.47). The network analysis identified drug interaction involving omeprazole and pantoprazole as the most relevant and related to the prescription of levothyroxine, clopidogrel and cilostazol. Conclusion: The drug interaction among proton pump inhibitors users increase with age and are more common in women, especially those associated with levothyroxine, cilostazol and clopidogrel.